35 results about "Platelet aggregation ratio" patented technology

The invention relates to a method for measuring the platelet aggregation and a blood coagulation factor. In the method, a full-automatic coagulate blood analytical instrument is used, the platelet aggregation is measured by using photoelectric turbidimetry and the blood coagulation factor is measured by using a double magnetic circuit and bead method. The method comprises the following measuring steps of: preparing a platelet aggregation inductive agent, platelet rich plasma and platelet poor plasma; respectively reading light transmittance data of a platelet poor plasma sample and light transmittance data of a platelet rich plasma sample as well as light transmittance data of the platelet rich plasma during the forming process of the platelet aggregation within the specified time; calculating the platelet aggregation rate of the measured blood sample; absorbing the platelet poor plasma and injecting the platelet poor plasma in a hemagglutination cup; absorbing the selected reagent according to a test program and injecting the selected reagent into the hemagglutination cup; automatically monitoring the amplitude of a steel bead; and generating a test report by using measuring results of the platelet aggregation and the blood coagulation factor according to input information of patients.

In this invention, we extract raw polysaccharides from changium root named A B C respectively, and purify to get 6 polysaccharides I,II,III,IV,V,VI. After sulfation, we get sulfated polysaccharides A1, B1,C1. A1 has two sulfate groups on each monosaccharide at the average while B1 and C1 have three. The sulfated polysaccharides' molecular weight is more than 2 million D. The glycoside link is alpha type. The whole procedure of changium root sulfated polysaccharides is as followings: extract raw polysaccharides from changium root, and then get the polysaccharides sulfated. It is advantageous in simplied-manipulation and low cost. The pharmacological experiments prove its obvious suppression on rat transplanting tumor(S-180) and the reduction of platelet aggregation ratio and whole blood viscosity. It also reduces coagulant time.

The invention provides an optimized automation-adaptable platelet aggregation function inspection and analysis method, and belongs to the field of clinical laboratory medicine. The method is an improvement and optimization of a platelet aggregation function inspection and analysis method using an automation counting method. The method is suitable for platelet aggregation function automatic analysis instruments using the counting method. According to the method, the number of platelets is inspected and recorded and an aggregation rate is calculated. A laboratory test result shows that the method is better in repeatability of the obtained result of platelet aggregation rate compared with a previous largest aggregation rate method.

The invention discloses a platelet aggregation determination method based on high throughput detection. The method comprises the following steps: extracting a platelet sample with activity from an organism, and diluting a platelet suspension through a solvent; and transferring into a microplate for incubation, adding a stimulant of certain concentration, and determining with a dynamical method of a microplate reader, thereby obtaining the platelet aggregation rate. The method can be applied to rapid clinical evaluation on activity of platelets and high throughput screening of antithrombotic drugs at multiple targets, and is implemented through a cyclooxygenase inhibitor, an ADP receptor inhibitor, a protein activating enzyme receptor inhibitor, a platelet surface GPIIb/IIIa receptor inhibitor and the like.

The invention relates to a platelet aggregation resisting drug. The platelet aggregation resisting drug comprises an atractylenolide-II derivative represented by a structural formula 1 shown in specifications. The invention further relates to application of an atractylenolide-II derivative in preparation of the platelet aggregation resisting drug. The platelet aggregation resisting drug, which is simple in composition and is prepared from effective ingredients of natural medicinal raw materials or effective ingredient extracts of the medicinal raw materials, provided by the invention has a good treatment effect, is free from toxic or side effects, is not prone to the generation of tolerance, is convenient to take and is generally applicable to the problems, such as viscous blood and thrombus, caused by too-high platelet aggregation rate.

The invention relates to a platelet aggregation resisting drug. The platelet aggregation resisting drug comprises an atractylenolide-III derivative represented by a structural formula 1 shown in specifications. The invention further relates to application of an atractylenolide-III derivative in preparation of the platelet aggregation resisting drug. The platelet aggregation resisting drug, which is simple in composition and is prepared from effective ingredients of natural medicinal raw materials or effective ingredient extracts of the medicinal raw materials, provided by the invention has a good treatment effect, is free from toxic or side effects, is not prone to the generation of tolerance, is convenient to take and is generally applicable to the problems, such as viscous blood and thrombus, caused by too-high platelet aggregation rate.

The invention relates to a method for determination of platelet aggregation rate. The method conducts determination on the basis of photoelectric turbidimetry, and comprises the determination steps of: placing prepared platelet-rich plasma onto a sample plate device, imbibing the platelet-rich plasma, injecting into a test cup of a test movement device, and reading the transmittance data of the platelet-rich plasma sample; imbibing a platelet aggregation inducer, injecting into a test cup, reading the transmittance data of the platelet-rich plasma sample within a specified time in the formation process of platelet aggregation; imbibing a strong inducer or a composite inducer, injecting into a test cup, conducting continuous detection on the test cup by a platelet aggregation test device; when all platelets in the platelet-rich plasma nearly reach the aggregation state and the maximum transmittance is reached, automatically reading the transmittance data; and calculating the maximum aggregation rate of the platelet of the measured blood sample, and generating a test report according to the input patient information.

The invention relates to the field of medicines, in particular to yak skin polypeptide with an effect of affecting platelet aggregation and a preparation method thereof. The yak protein is composed of17KDa, 34 KDa and 43 KDa in molecular weight. The maximum ultraviolet absorption wavelength of a peptide bond is at the 216nm position, the infrared spectrum of an amide I band is at the 1600-1700 cm-1 position, the infrared spectrum of an amide II band is at the 1560-1500cm position, and the infrared spectrum of the amide III is at the 1234-1237 cm-1 position. The preparation method includes buffing, heating, foaming, enzymatic hydrolysate preparation, centrifugal concentration and separation and drying. The pure natural pollution-free Qinghai-Tibet Plateau yak skin is used as the main raw material, the raw material source is wide, and the nutrition is rich. A product with the effect of affecting platelet aggregation is increased while the economic value added of the yak skin is increased. The polypeptide is simple in preparation and operation process. The prepared yak skin polypeptide has three molecular weight segments of bioactive components affecting the platelet aggregation, andthe platelet aggregation rate in vitro of mice is 38.4%.

The invention discloses a new multifunctional platelet detecting instrument which is a multifunctional detecting instrument with the functions of detecting the number, the volume size and the aggregation rate of platelets. The instrument realizes the function of detecting the aggregation ability (aggregation rate) of the platelets by detecting the changes of the platelets after platelet agonist is added. The blood sample which is not subjected to separation process is directly adopted to detect by the instrument; the operation process is convenient, influencing factor is few, and during the detecting process, the sample processing conditions (temperature, time, dosage of the reagent and so on) is automatically controlled to be consistent by the instrument, so the detection result is more reliable.

The invention provides a method for judging the measuring result of the platelet aggregation rate. The method comprises the following steps: a normal whole blood sample is selected, the anaemic platelet plasma transmittance PPP0 and the blood-rich platelet plasma transmittance PRP0 are measured, and the transmittance difference P0 of the whole blood sample is calculated, wherein P0=PPP0-PRP0; a measured whole blood sample is selected, the anaemic platelet plasma transmittance PPP and the blood-rich platelet plasma transmittance PRP are measured, and the transmittance difference P of the measured sample is calculated, wherein P=PPP-PRP; the platelet separation degree index DI of the measured sample is calculated, wherein DI=P/P0=(PPP-PRP)/(PPP0-PRP0); the platelet aggregation rate of blood-rich platelet plasma is measured through a platelet aggregator; and whether the measured platelet aggregation rate is reliable or not is judged according to the platelet separation degree index DI ofthe measured sample. According to the method for judging the measuring result of the platelet aggregation rate, by referring to the platelet separation degree index of the measured sample, the measuring result of the platelet aggregation rate of the measured sample is judged reliably.

The invention discloses application of a butyric acid compound in preparing a drug or functional food for treating ischemic stroke. The drug or the functional food comprises the butyric acid compound,wherein the concentration of the butyric acid compound is 20-100 micromoles per liter, and the effective dose of the butyric acid compound as the drug is 5-50 mg/kg/d. After oral administration, thebutyric acid compound can effectively reduce the area of cerebral infarction, significantly restore the neurological damages caused by the ischemic stroke, ameliorate dyslipidemia caused by the ischemic stroke, and effectively reduce the blood viscosity, the fibrinogen content and the platelets aggregation rate, thereby ameliorating the complications induced by the ischemic stroke in many aspectsand effectively treating the ischemic stroke.

The invention discloses a medicament for treating the chronic cerebral circulation insufficiency and a preparation method. The medicament comprises salvia, codonopsis, coptis, chuanxiong, zedoary, crataegus, seaweed, gastrodia, coix seed and curcuma as raw materials. The preparation method comprises the following steps of: adding water to the coptis for decoction, concentrating the water decoction into thick paste, adding water to other raw materials for decoction, concentrating the water decoction into thick paste, combing the two pieces of thick paste, adding a suitable amount of dextrin, and uniformly mixing, drying, crushing and pelletizing the mixture. The medicament has the effects of simultaneously removing blood stasis, promoting blood circulation, eliminating phlegm and invigorating spleen, can better treat the arteriosclerosis, remarkably improve the integral of syndrome of intermingled phlegm and blood stasis for the granule fraction of removing blood stasis and promoting blood circulation, has better effects of reducing the whole blood high-shear viscosity, low-shear viscosity, plasma viscosity and platelet aggregation ratio, and has the advantages of high safety and no influence on hemogram, liver and kidney functions and the like.

The invention discloses an application of isolated compounds from Salvia deserta Schang in the preparation of a drug with the anti-platelet aggregation effect. The application of the isolated compounds from Salvia deserta Schang in the preparation of the drug with the anti-platelet aggregation effect provided by the invention has the following benefits: according to in-vitro anti-platelet aggregation experiments on 7-O-acetylhorminone and horminone, the two componential monomers achieve better anti-platelet aggregation effect, certain quality dependency is shown among various concentration groups, and certain time dependency is shown among high concentration groups of the two components based on the fact that as time passes by, the platelet aggregation rate decreases and the inhibition rate increases; anti-platelet aggregation activity results indicate better activity of the two components, so that certain development and utilization value are achieved. The application can make up for the regional defect that Salvia miltiorrhiza drugs are absent in Xinjiang, thereby having remarkable market prospects.

The invention belongs to the technical field of Chinese medicine, and particularly relates to essential oil for activating blood and dredging collaterals. The essential oil comprises, by weight, 40-90 parts of jizhou mugwort leaf essential oilx, 30-70 parts of rhizoma corydalis essential oil, 36-76 parts of perilla leaf essential oil, 20-87 parts of garden balsam stem essential oil, 40-68 parts of carthamus tinctorius essential oil, 42-77 parts of chuanxiong rhizome essential oil and 30-75 parts of suberect spatholobus stem essential oil. The Chinese herbs are used as raw materials, an oxidation-resistant extracting solution is adopted for extracting the essential oil, and then all the essential oil is mixed according to a proportion to obtain the essential oil. The essential oil for activating blood and dredging collaterals has the remarkable effects that the aggregation rate of platelets is remarkably decreased, and blood viscosity and the wet weight of thrombus are remarkably reduced, and the effect of activating blood and dredging collaterals is remarkable; in the essential oil for activating blood and dredging collaterals, the chuanxiong rhizome essential oil and suberect spatholobus stem essential oil have a synergistic effect. The oxidation-resistant extracting solution is adopted for extracting the essential oil, so that the extracting rate of essential oil components is increased.

The invention belongs to the field of the traditional Chinese medicine and specifically relates to a traditional Chinese medicine compound with a stronger hemostasis function. An artemisia argyi preparatum traditional Chinese medicine compound with the stronger hemostasis function is prepared from the following raw materials: artemisia argyi preparatum, radix angelicae and vinegar processed corydalis tuber. The artemisia argyi preparatum traditional Chinese medicine compound can be used as a hemostasis drug or a main component in the hemostasis drug. According to the invention, the artemisia argyi preparatum is taken as the main component and the radix angelicae and the vinegar processed corydalis tuber are taken as auxiliary components; the determination for plasma recalcification time, the determination for platelet aggregation rate, the determination for thrombin activity promoting rate and the determination for platelet adhesiveness rate prove that the hemostasis effect of the artemisia argyi preparatum traditional Chinese medicine compound is obviously better than that of single artemisia argyi preparatum and is equivalent to that of Yunnan Baiyao powder; and the artemisia argyi preparatum traditional Chinese medicine compound can be used as a daily or clinical hemostasis drug.

A composite medicine for treating arrhythmia contains cilazapril (5-20 weight portions) and valsartan (40-240 weight portions).

The invention discloses a platelet aggregation rate detection method which comprises the steps: activating and aggregating platelets, crosslinking the platelets with magnetic beads coated with fibrinogen on the surfaces, aggregating the crosslinked activated platelets to a certain specific area by using magnetic force, and measuring the concentration of unactivated platelets in samples in other areas; and calculating the platelet aggregation rate according to the initial concentration of the platelets and the concentration of the unactivated platelets. By adopting the method provided by the invention, the influence on platelet aggregation in the detection process and the influence on quantity measurement caused by different aggregation conditions of platelets are avoided, and the detectionaccuracy is effectively improved.

The invention discloses an in-vitro evaluation model and an in-vitro evaluation method for hemostatic performance of toothpaste containing a bletilla striata extract. Evaluation indexes of the in-vitro evaluation model comprise at least one of platelet aggregation rate, cyclic adenosine monophosphate (cAMP) and thromboxane B2 (TXB2) content. The in-vitro evaluation method comprises the steps of: acquiring arterial blood of an animal, centrifuging the arterial blood, adjusting plasma concentration, and detecting absorbance OD0 when the arterial blood is blank; respectively adding a toothpaste sample containing bletilla striata extracts with different concentrations and a control sample into a pore plate filled with blood plasma, slightly oscillating the samples, incubating the samples at aconstant temperature of 37 DEG C for full reaction, and adding an adenosine diphosphate solution into the samples to induce platelet aggregation reaction; and testing plasma absorbance ODt and contentof cAMP and TXB2 when the turbidity in the reaction system changes, and calculating a platelet aggregation rate for evaluating the hemostatic performance of the toothpaste. The in-vitro evaluation model and the in-vitro evaluation method effectively reduce and avoid the usage of experimental animals, can greatly improve the working efficiency of toothpaste formula research, and reduce the in-vivotest cost.